company background image
EQL logo

EQL Pharma NGM:EQL 株式レポート

最終価格

kr50.00

時価総額

kr1.5b

7D

-3.5%

1Y

68.9%

更新

19 Jun, 2024

データ

会社財務 +

EQL Pharma AB (publ)

NGM:EQL 株式レポート

時価総額:kr1.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

EQL 株式概要

EQL Pharma AB(publish)は、スウェーデン、デンマーク、ノルウェー、フィンランド、その他ヨーロッパの薬局や病院向けにジェネリック医薬品の開発、マーケティング、販売を行っている。

EQL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance1/6
Financial Health3/6
Dividends0/6

EQL Pharma AB (publ) 競合他社

価格と性能

Summary of all time highs, changes and price drops for EQL Pharma
Historical stock prices
Current Share Pricekr50.00
52 Week Highkr55.00
52 Week Lowkr24.70
Beta0.72
1 Month Change11.11%
3 Month Change31.58%
1 Year Change68.92%
3 Year Change38.89%
5 Year Change318.41%
Change since IPO762.07%

最新ニュース

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

株主還元

EQLSE HealthcareSE 市場
7D-3.5%1.2%-1.1%
1Y68.9%29.8%13.9%

業界別リターン: EQL過去 1 年間で28.1 % の収益を上げたSwedish Healthcare業界を上回りました。

リターン対市場: EQL過去 1 年間で13 % の収益を上げたSwedish市場を上回りました。

価格変動

Is EQL's price volatile compared to industry and market?
EQL volatility
EQL Average Weekly Movement5.6%
Healthcare Industry Average Movement5.2%
Market Average Movement5.9%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market3.5%

安定した株価: EQL過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: EQLの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
200621Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publish)は、スウェーデン、デンマーク、ノルウェー、フィンランド、その他ヨーロッパの薬局や病院向けにジェネリック医薬品の開発、マーケティング、販売を行っている。入院治療用の注射剤と外来治療用の製剤を提供している。EQL Pharma AB(publ)は2006年に設立され、スウェーデンのルンドに本社を置いている。

EQL Pharma AB (publ) 基礎のまとめ

EQL Pharma の収益と売上を時価総額と比較するとどうか。
EQL 基礎統計学
時価総額kr1.45b
収益(TTM)kr22.71m
売上高(TTM)kr264.17m

64.0x

PER(株価収益率

5.5x

P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
EQL 損益計算書(TTM)
収益kr264.17m
売上原価kr149.12m
売上総利益kr115.05m
その他の費用kr92.34m
収益kr22.71m

直近の収益報告

Mar 31, 2024

次回決算日

Jun 28, 2024

一株当たり利益(EPS)0.78
グロス・マージン43.55%
純利益率8.59%
有利子負債/自己資本比率67.6%

EQL の長期的なパフォーマンスは?

過去の実績と比較を見る